Head-to-head evidence
Cofrogliptin vs DBPR108
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Cofrogliptin
Developed by Haisco Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT07019012 (registry estimate)
DBPR108
Developed by CSPC Pharmaceutical Group
NCT04161430 · Phase 3 · completed
In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · DBPR108's landscape